(0.28%) 5 145.75 points
(0.16%) 38 504 points
(0.42%) 17 922 points
(-0.68%) $83.28
(2.13%) $1.964
(-0.14%) $2 344.00
(-0.11%) $27.51
(2.81%) $948.00
(-0.03%) $0.934
(-0.09%) $11.01
(-0.26%) $0.798
(1.85%) $93.57
@ $0.735
发出时间: 15 Feb 2024 @ 03:11
回报率: -29.52%
上一信号: Feb 14 - 04:21
上一信号:
回报率: 6.03 %
Live Chart Being Loaded With Signals
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation...
Stats | |
---|---|
今日成交量 | 662 849 |
平均成交量 | 2.44M |
市值 | 105.46M |
EPS | $0 ( 2024-03-13 ) |
下一个收益日期 | ( $-0.220 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.350 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-24 | Pooler Amy | Sell | 2 209 | Common Stock |
2024-02-25 | Pooler Amy | Sell | 2 459 | Common Stock |
2024-02-24 | Willoughby Scott B. | Sell | 4 379 | Common Stock |
2024-02-25 | Willoughby Scott B. | Sell | 3 453 | Common Stock |
2024-02-24 | Dubois-stringfellow Nathalie | Sell | 5 474 | Common Stock |
INSIDER POWER |
---|
3.11 |
Last 100 transactions |
Buy: 7 300 210 | Sell: 7 415 564 |
音量 相关性
Sangamo Therapeutics Inc 相关性 - 货币/商品
Sangamo Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $176.23M |
毛利润: | $154.04M (87.41 %) |
EPS: | $-1.480 |
FY | 2023 |
营收: | $176.23M |
毛利润: | $154.04M (87.41 %) |
EPS: | $-1.480 |
FY | 2022 |
营收: | $111.30M |
毛利润: | $99.19M (89.12 %) |
EPS: | $-1.250 |
FY | 2021 |
营收: | $110.70M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.230 |
Financial Reports:
No articles found.
Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。